CA Patent

CA3105501C — Selective estrogen receptor degraders

Assigned to Eli Lilly and Co · Expires 2023-10-31 · 3y expired

What this patent protects

Selective estrogen receptor degraders (SERDs) according to the formula: (see above formula) pharmaceutically acceptable salts, pharmaceutical compositions, uses for treating cancer such as treating breast cancer, ovarian cancer, endometrial cancer, prostate cancer, uterine cancer…

USPTO Abstract

Selective estrogen receptor degraders (SERDs) according to the formula: (see above formula) pharmaceutically acceptable salts, pharmaceutical compositions, uses for treating cancer such as treating breast cancer, ovarian cancer, endometrial cancer, prostate cancer, uterine cancer, gastric cancer, or lung cancer.

Drugs covered by this patent

Patent Metadata

Patent number
CA3105501C
Jurisdiction
CA
Classification
—
Expires
2023-10-31
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.